RAPT Therapeutics CMO Granted $557K in Stock Options, Signals Growth Plans
RAPT Therapeutics Chief Medical Officer William Ho received a new stock option grant on June 20, 2025.
Rhea-AI Filing Summary
RAPT Therapeutics Chief Medical Officer William Ho received a new stock option grant on June 20, 2025. The derivative securities transaction details include:
- Grant of 75,000 employee stock options
- Exercise price set at $7.43 per share
- Options expire on June 19, 2035
- Vesting schedule: 1/48th of shares vest monthly from June 20, 2025
This Form 4 filing, signed by attorney-in-fact Rodney Young, represents a standard equity compensation grant to a key executive officer. The ten-year option grant suggests a long-term retention strategy for the Chief Medical Officer position. The monthly vesting schedule over four years aligns with typical industry practices for executive compensation.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (right to buy) | 75,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. 1/48th of the shares subject to the option shall vest on each monthly anniversary of the vesting commencement date of June 20, 2025.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stock options were granted to RAPT Therapeutics' Chief Medical Officer William Ho in June 2025?
What is the vesting schedule for William Ho's RAPT stock options granted in June 2025?
Who filed the Form 4 for RAPT Therapeutics (RAPT) on June 28, 2025?
What is the total value of RAPT stock options granted to William Ho in June 2025?
AI-generated analysis. How Rhea-AI works. Not financial advice.